Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team at Oxford University are sharing an epidemiological model to help configure a contact tracing app for coronavirus. The model offers several safe configurations to introduce an app and a framework to optimise the app after it is released. The simulations confirm that if around half the total population use the app, alongside other interventions, it has the potential to stop the epidemic and help to keep countries out of lockdown. These research efforts are supporting several European projects including the UK’s national programme led by NHSX, a joint unit comprised of teams from NHS England and the Department of Health & Social Care.

After analysis of the transmission dynamics of the early coronavirus epidemic in China, the Oxford team demonstrated that almost half of all transmissions occurred before anyone showed symptoms. They also estimated that delaying contact tracing by even a day from the onset of symptoms could make the difference between epidemic control and coronavirus resurgence. To respond to this, the team rapidly conceptualised a simple mobile contact tracing app to help control the spread of coronavirus, save lives and ease the population out of lockdown.

Read the full story on the Big Data Institute website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.